Axiogenesis AG, a leading global provider of in vitro models of healthy and diseased human cell types derived from induced pluripotent stem cells (iPSC), has announced that researchers within the United States Food & Drug Administration (FDA) Center for Devices & Radiological Health will study the use of Cor.4U® human iPSC-derived cardiomyocytes within assays that investigate the safety of drug compounds.
Under the agreement, the FDA will perform in vitro experiments with Cor.4U® human iPSC cardiomyocytes to assess the electrophysiological response of the cells in the presence and absence of known pharmaceutical compounds.
The pharmaceutical industry currently suffers from not having relevant models in which to test the efficacy and safety of potential therapies in early development. "Human iPSC-derived cell types, such as Cor.4U® pure cardiomyocytes, offer a translational human model to test drug effects in high throughput systems", said Heribert Bohlen MD, CEO of Axiogenesis. "This allows pharmaceutical companies to assess the potential safety risk of a compound in human cells before they invest millions of dollars in drug development."
About Axiogenesis AG
Since 2000, Axiogenesis has been in business to capture the promise of stem cells to revolutionize the fields of drug discovery & development and life sciences research. Axiogenesis develops and commercializes stem cell-derived, in vitro differentiated cardiomyocytes and other cell types, as well as drug development assays and disease models, to help researchers discover cures. Visit www.axiogenesis.com.
Felix von Haniel
Director of Business Development
+49 221 998818-0